Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Opinion

Sort by: Newest first Oldest first A-Z Z-A

  • NHS England continues to add insult to injury with regard to PrEP funding Subscription

    On 2 August 2016, the National AIDS Trust (NAT) won its judicial review of NHS England’s removal of pre-exposure prophylaxis (PrEP), the highly effective HIV prevention drug, from its commissioning process. The judge ruled that NHS England was wrong to assert that it cannot fund PrEP because it is a prevention intervention.

  • NHS England has a clear role in commissioning PrEP Subscription

    On 31 May 2016, NHS England confirmed it would remove pre-exposure prophylaxis (PrEP, an HIV prevention drug which has been proven to be effective) from the NHS specialised commissioning process.

  • Providing HIV care in community pharmacy Subscription

    By Kirsteen Hill

    HIV is a long-term, chronic condition which is usually only managed by clinical teams in secondary care and antiretroviral (ARV) treatment is usually supplied by hospital pharmacies or homecare companies.

  • NHS England’s backtracking on its refusal to fund pre-exposure prophylaxis (PrEP) funding is a step forward for public health Subscription

    In March 2016, NHS England removed HIV prevention drug pre-exposure prophylaxis (PrEP) from its official commissioning process — just months before it was due to conclude.

  • NHS England pulling the plug on PrEP for HIV prevention is unacceptable Subscription

    I wish to draw your attention to NHS England’s sudden abandonment of its own processes in a shocking U-turn on access to HIV game changer pre-exposure prophylaxis (PrEP; emtricitabine/tenofovir, marketed as Truvada).

  • Flawed decision from NHS England on pre-exposure prophylaxis (PrEP) for HIV prevention Subscription

    Like the countless people affected by HIV in the UK, we are angry and confused by the decision of NHS England to halt its work to ensure that pre-exposure prophylaxis (PrEP; (emtricitabine/tenofovir, marketed as Truvada), which drastically reduces the chance of infection with HIV, is available on the NHS. We know that PrEP is efficient and cost-effective and we share the frustration that NHS England has pulled the plug on more than 18 months of hard work.

  • Daklinza licence extension Subscription

    Daklinza (daclatasvir; Bristol Myers Squibb), used in combination with other drugs to treat hepatitis C, has been approved for extended use for patients co-infected with HIV and also post liver transplantation by the European Medicines Agency. 

  • January 2016: AWMSG approvals Subscription

    The All Wales Medicines Strategy Group (AWMSG) has approved the following medicines for use by the NHS in Wales: atazanavir/cobicistat (Evotaz) for adults infected with human immunodeficiency virus-1 (HIV-1); efavirenz (Sustiva) for children aged between 3 months and 3 years who are infected with HIV-1; macitentan (Opsumit) for adults with pulmonary arterial hypertension (only where the approved patient access scheme is used); empagliflozin (Jardiance) for type 2 diabetes. Full details ...

  • December 2015: AWSMG approvals Subscription

    The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Abasaglar (a biosimilar of insulin glargine; Eli Lilly and Company) for diabetes mellitus in patients aged 2 years and above. Sucroferric oxyhydroxide (Velphoro; Vifor Fresenius Medical Care Renal Pharma) for controlling serum phosphorus levels in adults with chronic kidney disease who are on haemodialysis or peritoneal dialysis where non-calcium based ...

  • Fuzeon product update Subscription

    The summary of product characteristics of the HIV medication Fuzeon (enfuvirtide; Roche) powder for solution for injection has been updated to warn that as a peptide, enfuvirtide can cause cutaneous amyloidosis at the injection site.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.